Watch These Hot Ones: Sprint Corporation (NYSE:S), Houston Wire & Cable Company (NASDAQ:HWCC), TG Therapeutics (NASDAQ:TGTX), Capricor Therapeutics (NASDAQ:CAPR)

Posted by on Mar 03, 2016

AT&T, Inc. (NYSE:T) shares advanced 0.80% in last trading session and ended the day at $37.99. T Gross Margin is 54.30% and its has a return on assets of 4.60%. AT&T, Inc. (NYSE:T) quarterly performance is 14.08%.

On 26 February, AT&T, Inc. (NYSE:T) donated a total of $62,500 to political committees in Missouri. This included $20,000 to the House Republican Campaign Committee, $20,000 to the Missouri Democratic State Committee, $7,500 to the Missouri Republican Party, and $15,000 to the Missouri Senate Campaign Committee (apparently a Republican group).

Sprint Corporation (NYSE:S) ended the last trading day at $4.00. Company weekly volatility is calculated as 7.82% and price to cash ratio as 7.17. Sprint Corporation (NYSE:S) showed a weekly performance of 30.29%.

On 26 February, Sprint Corporation (NYSE:S) has decided to revive two-year contracts. That makes it the only one of the big four carriers in the US still offering the 24-month payment plan.

Houston Wire & Cable Company (NASDAQ:HWCC) ended the last trading day at $5.77. Company weekly volatility is calculated as 5.07%. Houston Wire & Cable Company (NASDAQ:HWCC) showed a weekly performance of 8.05%.

Houston Wire & Cable Company (NASDAQ:HWCC) will hold a conference call on Thursday, March 10, 2016, at 10:00 a.m. C.T., to discuss Fourth Quarter 2015 results. Hosting the call will be James Pokluda, President & Chief Executive Officer and Nicol Graham, Vice President & Chief Financial Officer.

TG Therapeutics, Inc. (NASDAQ:TGTX) shares decreased -2.55% in last trading session and ended the day at $9.19. TGTX has a return on assets of -56.40%. TG Therapeutics, Inc. (NASDAQ:TGTX) quarterly performance is -35.19%.

TG Therapeutics Inc (NASDAQ:TGTX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Tuesday, ARN reports. The firm currently has a $9.25 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective would indicate a potential upside of 11.04% from the stock’s current price.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) caters to the Healthcare space. Its weekly performance is -10.00%. On the last day of trading company shares ended up at $2.25. Capricor Therapeutics, Inc. (NASDAQ:CAPR) distance from 50-day simple moving average (SMA50) is 1.42%.

On 23 February, Capricor Therapeutics, Inc. (NASDAQ:CAPR) announced the appointment of Leland J. Gershell, M.D., Ph.D. as Chief Financial Officer. Dr. Gershell brings to Capricor over 15 years of experience in the biotech sector, both within the industry and in finance as an equity research analyst and healthcare investor. He will report to Dr. Linda Marbán, Capricor’s Chief Executive Officer. His appointment is effective immediately.

Leave a Reply

Your email address will not be published. Required fields are marked *